{"id":51315,"date":"2022-11-28T22:02:25","date_gmt":"2022-11-28T21:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/"},"modified":"2022-11-28T22:02:25","modified_gmt":"2022-11-28T21:02:25","slug":"cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/","title":{"rendered":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform"},"content":{"rendered":"
\n

BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company\u2019s Shielded-Cell & Immunotherapy Pairs (SCIP) platform.\n<\/p>\n

<\/a><\/p>\n

\nU.S. Patent No. 11,499,168 covers a method for in vivo<\/i> selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D., Ph.D., at the University of Basel, and is exclusively licensed to Cimeio.\n<\/p>\n

\n\u201cThis comprehensive intellectual property provides broad protection for our platform,\u201d said Cimeio CEO Thomas Fuchs. \u201cWe believe this patent, along with those we\u2019ve filed for our target antigen and immunotherapy portfolio, cements us as a leader in the emerging field of cell shielding and will enable the broad development of our SCIP platform.\u201d\n<\/p>\n

\nCimeio uses genome editing to insert novel protein variants into hematopoietic stem cells or other types of cells, allowing the cells to maintain their function while making them resistant to paired immunotherapy depletion. Cimeio\u2019s platform has effectively shielded cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells in preclinical studies.\n<\/p>\n

\nThe company is advancing its first programs towards clinical development for genetic and malignant hematologic diseases. As previously disclosed, two posters for the company\u2019s pipeline programs will be presented at the American Society of Hematology meeting in December 2022 in New Orleans.\n<\/p>\n

\nAbout Cimeio<\/b>\n<\/p>\n

\nCimeio is an applied gene editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs\u00ae (SCIP), which has the potential to transform hematopoietic stem cell transplant. Cimeio\u2019s technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders. For more information, please visit www.cimeio.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSteve Edelson
\n
sedelson@versantventures.com<\/a>
415-801-8088\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company\u2019s Shielded-Cell & Immunotherapy Pairs (SCIP) platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51315","6":"format-standard","7":"category-industry"},"yoast_head":"\nCimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company\u2019s Shielded-Cell & Immunotherapy Pairs (SCIP) platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-28T21:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform\",\"datePublished\":\"2022-11-28T21:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/\"},\"wordCount\":376,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221128005659\\\/en\\\/1648440\\\/21\\\/Cimeio_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/\",\"name\":\"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221128005659\\\/en\\\/1648440\\\/21\\\/Cimeio_logo.jpg\",\"datePublished\":\"2022-11-28T21:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221128005659\\\/en\\\/1648440\\\/21\\\/Cimeio_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221128005659\\\/en\\\/1648440\\\/21\\\/Cimeio_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/","og_locale":"en_US","og_type":"article","og_title":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend","og_description":"BASEL, Switzerland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company\u2019s Shielded-Cell & Immunotherapy Pairs (SCIP) platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-28T21:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform","datePublished":"2022-11-28T21:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/"},"wordCount":376,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/","url":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/","name":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg","datePublished":"2022-11-28T21:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221128005659\/en\/1648440\/21\/Cimeio_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cimeio-therapeutics-announces-issuance-of-key-patent-covering-cell-therapy-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51315"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51315\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}